Humana (NYSE:HUM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The brokerage presently has a $373.00 price objective on the insurance provider’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 21.90% from the stock’s previous close.
According to Zacks, “Humana’s shares have outperformed its industry’s growth in a year’s time. Moreover, it has witnessed its 2018 and 2019 earnings estimates move upward over the past 30 days. The insurer is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Sufficient generation of cash flow has helped the company take up many capital deployment initiatives aimed at enhancing its shareholder value. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. However, its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects to witness rise in benefit expenses which will lead to an overall increase in operating expenses going forward.”
HUM has been the topic of a number of other reports. Jefferies Financial Group upped their price target on shares of Humana from $388.00 to $410.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. MED upped their price target on shares of Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research note on Thursday, November 8th. Bank of America upped their price target on shares of Humana from $400.00 to $415.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. Royal Bank of Canada upped their price target on shares of Humana from $318.00 to $349.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 8th. Finally, Credit Suisse Group upped their price target on shares of Humana from $370.00 to $390.00 and gave the stock an “outperform” rating in a research note on Thursday, November 8th. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana has a consensus rating of “Buy” and a consensus target price of $352.10.
Shares of HUM opened at $306.00 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. The firm has a market capitalization of $43.39 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 1.50 and a beta of 0.99. Humana has a 1 year low of $242.00 and a 1 year high of $355.88.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same period in the previous year, the company posted $3.39 EPS. As a group, equities research analysts expect that Humana will post 14.43 EPS for the current year.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now directly owns 71,085 shares in the company, valued at approximately $23,362,796.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roy A. Beveridge sold 4,622 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the completion of the sale, the insider now owns 10,621 shares in the company, valued at $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Honkamp Krueger Financial Services Inc. purchased a new position in Humana in the 3rd quarter valued at about $108,000. Stratos Wealth Partners LTD. purchased a new position in Humana in the 3rd quarter valued at about $108,000. Sun Life Financial INC lifted its holdings in Humana by 120.7% in the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 388 shares during the last quarter. Finally, Smithfield Trust Co. increased its stake in shares of Humana by 531.2% during the 3rd quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after acquiring an additional 409 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Article: Return on Equity (ROE)
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.